RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS SCIE

      Improving vaccines by targeting antigens to dendritic cells

      한글로보기

      https://www.riss.kr/link?id=A101635433

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      A new approach to enhancing the effectiveness of vaccines is to deliver antigens selectively to dendritic cells (DC) in situ, via monoclonal antibodies specific for particular DC surface molecules. This can markedly enhance CTL responses and, via help...

      A new approach to enhancing the effectiveness of vaccines
      is to deliver antigens selectively to dendritic cells
      (DC) in situ, via monoclonal antibodies specific for particular
      DC surface molecules. This can markedly enhance
      CTL responses and, via helper T cells, also enhance
      antibody responses. DC activation agents or adjuvants
      must also be administered for effective CTL responses,
      but in some cases good antibody responses
      can be obtained without adjuvants. Here we review the
      role of different DC subsets and different DC target molecules
      in obtaining enhanced immune responses.

      더보기

      다국어 초록 (Multilingual Abstract)

      A new approach to enhancing the effectiveness of vaccines is to deliver antigens selectively to dendritic cells (DC) in situ, via monoclonal antibodies specific for particular DC surface molecules. This can markedly enhance CTL responses and, via ...

      A new approach to enhancing the effectiveness of vaccines
      is to deliver antigens selectively to dendritic cells
      (DC) in situ, via monoclonal antibodies specific for particular
      DC surface molecules. This can markedly enhance
      CTL responses and, via helper T cells, also enhance
      antibody responses. DC activation agents or adjuvants
      must also be administered for effective CTL responses,
      but in some cases good antibody responses
      can be obtained without adjuvants. Here we review the
      role of different DC subsets and different DC target molecules
      in obtaining enhanced immune responses.

      더보기

      참고문헌 (Reference)

      1 Sancho D, "Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin" 118 : 2098-110, 2008

      2 Tacken PJ, "Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting" 7 : 790-802, 2007

      3 Trumpfheller C, "The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine" 105 : 2574-9, 2008

      4 Schnorrer P, "The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture" 103 : 10729-34, 2006

      5 Steinman RM, "The dendritic cell system and its role in immunogenicity" 9 : 271-96, 1991

      6 Caminschi I, "The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement" 112 : 3264-73, 2008

      7 Iyoda T, "The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo" 195 : 1289-302, 2002

      8 Skea DL, "Studies of the adjuvant-independent antibody response to immunotargeting. Target structure dependence, isotype distribution, and induction of long term memory" 151 : 3557-68, 1993

      9 Shortman K, "Steady-state and inflammatory dendritic-cell development" 7 : 19-30, 2007

      10 Mukhopadhaya A, "Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice" 2008

      1 Sancho D, "Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin" 118 : 2098-110, 2008

      2 Tacken PJ, "Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting" 7 : 790-802, 2007

      3 Trumpfheller C, "The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine" 105 : 2574-9, 2008

      4 Schnorrer P, "The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture" 103 : 10729-34, 2006

      5 Steinman RM, "The dendritic cell system and its role in immunogenicity" 9 : 271-96, 1991

      6 Caminschi I, "The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement" 112 : 3264-73, 2008

      7 Iyoda T, "The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo" 195 : 1289-302, 2002

      8 Skea DL, "Studies of the adjuvant-independent antibody response to immunotargeting. Target structure dependence, isotype distribution, and induction of long term memory" 151 : 3557-68, 1993

      9 Shortman K, "Steady-state and inflammatory dendritic-cell development" 7 : 19-30, 2007

      10 Mukhopadhaya A, "Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice" 2008

      11 Tagliani E, "Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8alpha+ dendritic cells" 180 : 3201-9, 2008

      12 Carter RW, "Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1" 177 : 2276-84, 2006

      13 Bruder D, "On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes" 54 : 3395-401, 2005

      14 Galibert L, "Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule" 280 : 21955-64, 2005

      15 Villadangos JA, "Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo" 7 : 543-55, 2007

      16 Pooley J, "Intravenous soluble antigen is presented to CD4 T cells by CD8- Dendritic cells but cross-presented to CD8+ T cells by CD8+ Dendritic cells" 166 : 5327-30, 2001

      17 Kretschmer K, "Inducing and expanding regulatory T cell populations by foreign antigen" 6 : 1219-27, 2005

      18 Bonifaz LC, "In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination" 199 : 815-24, 2004

      19 Reis e Sousa C, "In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas" 186 : 1819-29, 1997

      20 Snider DP, "Enhanced antigen immunogenicity induced by bispecific antibodies" 171 : 1957-63, 1990

      21 Bonifaz L, "Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance" 196 : 1927-38, 2002

      22 Burgdorf S, "Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation" 316 : 612-6, 2007

      23 Hochrein H, "Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets" 166 : 5448-55, 2001

      24 Dudziak D, "Differential antigen processing by dendritic cell subsets in vivo" 315 : 107-11, 2007

      25 Wykes M, "Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response" 161 : 1313-9, 1998

      26 Hawiger D, "Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo" 194 : 769-79, 2001

      27 Finkelman FD, "Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion" 157 : 1406-14, 1996

      28 Schulz O, "Cross-presentation of cellassociated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells" 107 : 183-9, 2002

      29 Huysamen C, "CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes" 2008

      30 Yamazaki S, "CD8+ CD205+splenic dendritic cells are specialized to induce Foxp3+regulatory T cells" 181 : 6923-33, 2008

      31 den Haan JM, "CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells In vivo" 192 : 1685-96, 2000

      32 Castro FV, "CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses" 38 : 2263-73, 2008

      33 He LZ, "Antigenic targeting of the human mannose receptor induces tumor immunity" 178 : 6259-67, 2007

      34 Boscardin SB, "Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses" 203 : 599-606, 2006

      35 Corbett AJ, "Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional "danger"" 35 : 2815-25, 2005

      36 Carayanniotis G, "Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC" 327 : 59-61, 1987

      37 Soares H, "A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70- dependent mechanism in vivo" 204 : 1095-106, 2007

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2009-09-21 학회명변경 한글명 : 대한생화학ㆍ분자생물학회 -> 생화학분자생물학회
      영문명 : Korean Society Of Medical Biochemistry And Molecular Biology -> Korean Society Of Biochemistry And Molecular Biology
      KCI등재
      2008-01-01 평가 SCI 등재 (등재유지) KCI등재
      2006-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2004-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2001-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      1998-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 3.74 0.23 2.56
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      1.82 1.45 0.555 0.01
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼